期刊
PHARMACOLOGY & THERAPEUTICS
卷 128, 期 1, 页码 1-36出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2010.04.015
关键词
Malignant glioma; Glioblastoma; Anaplastic astrocytoma; Chemotherapy; Biologic therapy; Immunotherapy; Clinical trial
资金
- National Institute of Neurological Disorders and Stroke, NIH
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH
- Howard Hughes Medical Institute-National Institutes of Health
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003026] Funding Source: NIH RePORTER
Malignant gliomas, which include glioblastomas and anaplastic astrocytomas, are the most common primary tumors of the brain. Over the past 30 years, the standard treatment for these tumors has evolved to include maximal safe surgical resection, radiation therapy and temozolomide chemotherapy. While the median survival of patients with glioblastomas has improved from 6 months to 14.6 months, these tumors continue to be lethal for the vast majority of patients. There has, however, been recent substantial progress in our mechanistic understanding of tumor development and growth. The translation of these genetic, epigenetic and biochemical findings into therapies that have been tested in clinical trials is the subject of this review. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据